This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The University of Chicago. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Xiaocheng Weng in Nucleic Acid Research
Introduction
Xiaocheng Weng is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of nucleic acid research, particularly through his innovative patent related to kethoxal derivatives. His work focuses on developing methods that enhance the understanding of RNA structures in live cells.
Latest Patents
Weng holds a patent titled "Compositions and methods related to kethoxal derivatives." This patent encompasses N-kethoxal reagents and derivatives, which facilitate fast and reversible labeling of single-stranded nucleic acids in live cells. One notable aspect of his invention is a process for reversible labeling of single-stranded guanine bases, which enables effective in vivo methods for transcriptome-wide RNA secondary structure mapping and RNA G-quadruplex prediction. He has 1 patent to his name.
Career Highlights
Xiaocheng Weng is affiliated with The University of Chicago, where he continues to advance research in his field. His work has garnered attention for its potential applications in understanding RNA dynamics and functions.
Collaborations
Weng collaborates with esteemed colleagues, including Chuan He and Tong Wu, who contribute to the innovative research environment at The University of Chicago.
Conclusion
Xiaocheng Weng's contributions to nucleic acid research through his innovative patent highlight the importance of advancements in understanding RNA structures. His work continues to pave the way for future discoveries in molecular biology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
